Osiris Crushed on Crohn’s Trial Design Flaw (OSIR)
Osiris Therapeutics, Inc. (NASDAQ: OSIR) is seeing its stock getting pounded this morning. The company announced that it was ending enrollment at 210 patients in its Phase III trial evaluating ...Read Full Story »















